Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1296Carcinoma, Non-Small-Cell Lung 793Neoplasms 787Colorectal Neoplasms 760Stomach Neoplasms 587Carcinoma, Hepatocellular 581Prostatic Neoplasms 514Lung Neoplasms 466Pancreatic Neoplasms 421Rectal Neoplasms 336Recurrence 314Neoplasm Metastasis 308Leukemia, Myeloid, Acute 293Colonic Neoplasms 283Multiple Myeloma 280Lymphoma 276Esophageal Neoplasms 273Uterine Cervical Neoplasms 272Ovarian Neoplasms 263Melanoma 246Head and Neck Neoplasms 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 210Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 187Nasopharyngeal Carcinoma 182Leukemia 173Lymphoma, Non-Hodgkin 171Liver Neoplasms 165Glioblastoma 160Polycystic Ovary Syndrome 157

Interventions

anlotinib 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Overall Survival × Clear all
NCT05218629 2023-03-29

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Qingdao Central Hospital

Phase 2 Unknown
20 enrolled

Overall Survival

NCT04050787 2019-08-08

Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer

The First Hospital of Jilin University

Phase NA Unknown
100 enrolled

Overall Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡